Artificial Intelligence

Two scientists in a research laboratory
#App note #Artificial intelligence (AI) #Assays #Cell culture #Cellular assays #Cellular imaging

Discover how to streamline migration assays with in-incubator monitoring

Cell migration assays can be time-consuming and challenging, from identifying and ensuring assays are imaged at the appropriate time, to properly measuring wound closure. In this new App Note, discover the benefits of Evident’s CM cell culture monitors, which provide label-free, quantitative results, consistent results throughout your lab, and are… Read More

#News

#Artificial intelligence (AI) #Assays #Cell culture #Cellular assays #Cellular imaging

Streamline migration assays with in-incubator monitoring

Cell migration assays can be time-consuming and challenging, from identifying and ensuring assays are imaged at the appropriate time, to properly measuring wound closure. Evident’s CM cell culture monitors provide label-free, quantitative results, consistent results throughout your lab, and are cost-effective. Researchers at ACEL simplified the cell migration process by… Read More

#Resources

#3D modelling #Artificial intelligence (AI) #BioPharmics #Computational chemistry #Mergers and acquisitions #Molecular Biology #Optibrium

Optibrium acquires BioPharmics

AI drug discovery company Optibrium has acquired 3D drug design specialist BioPharmics. BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, will join the Optibrium team, respectively focusing on R&D and Application Science in the newly-created BioPharmics Division. BioPharmics has developed a series of algorithms and… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More

#News

AI brain
#Artificial intelligence (AI) #Financing #Funding #Genesis Therapeutics

AI drug discovery company closes $200m Series B financing

A Series B financing round has raised Genesis Therapeutics’ total capital to over $280 million, which will be used to bring the company’s artificial intelligence (AI)-enabled pipeline into clinical development. Genesis will also invest in continued development of generative and predictive AI methods, which form the foundation of the Genesis… Read More

#Business & Investment #News

Human neurone
#Artificial intelligence (AI) #Francis Crick Institute #Neurodegenerative disorders #Neurology #Parkinson's #Personalised medicine

AI Parkinson’s discovery paves way for personalised treatments

A new study has demonstrated that machine learning can accurately predict subtypes of Parkinson’s disease using images of patient-derived stem cells, paving the way for personalised medicine and targeted drug discovery. The work, by the Francis Crick Institute, UCL Queen Square Institute of Neurology, and technology… Read More

#News #Trending News

AI brain
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #EMA #Machine learning

EMA urges “human-centric approach” to AI in drug discovery

The European Medicines Association (EMA) has published a draft reflection paper outlining the current thinking on the use of artificial intelligence (AI) to support the safe and effective development, regulation and use of medicines. The paper, which is now open for public consultation, reflects on principles relevant to the application… Read More

#News #Regulatory

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug design #Gero #Quantum computing

Study demonstrates power of quantum computing in drug design

In a new scientific paper, AI-driven biotech Gero has demonstrated the feasibility of applying quantum computing to drug design and generative chemistry. The research, published in Scientific Reports, outlines how a hybrid quantum-classical machine-learning model was used to interface between classical and quantum computational devices with… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

DDW Highlights podcast: New episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

This week in drug discovery (3-7 July)  

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery… Read More

#News

#Artificial intelligence (AI) #Cancer research #Collaboration #Oncology #Precision medicine #The Institute of Cancer Research #Vivan Therapeutics

AI discovery collaboration targets precision cancer drugs

Researchers will combine expertise in drug discovery, artificial intelligence (AI), and experimental cancer models and platforms in a new programme to design the precision cancer drugs of the future. Under an academic and commercial collaboration between The Institute of Cancer Research, London, the Bellvitge Biomedical Research… Read More

#Cancer Research #News

Big data concept image
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Data science #Machine learning

Big data – charting a new path to drug discovery and development

Listen to this article on the DDW Podcast: Tim Lowery, President, JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology. Drug discovery and development timelines can span 10-15… Read More

#Exclusive Content

Ageing hands
#Age-related diseases (ARDs) #Ageing #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #University of Edinburgh

AI algorithms find drugs that could combat ageing

Three drugs that could help stave off the effects of ageing have been discovered using artificial intelligence (AI), a study by Edinburgh researchers suggests. Findings suggest the drugs can safely remove defective cells – known as senescent cells – linked to conditions including cancer, Alzheimer’s disease… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Machine learning #Monoclonal antibodies #mRNA #Precision medicine

Right on target: The shift to precision pharmaceuticals

By DDW Editor Reece Armstrong. If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World, it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Artificial intelligence (AI), gene editing, synthetic… Read More

#Exclusive Content

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

New DDW Highlights episode live now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive… Read More

#News